Trials / Completed
CompletedNCT00973011
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy
A Phase Ia, Multicenter, Open-Label, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The Phase Ia, open-label, multicenter study will consist of a single-dose, dose-escalation study of the safety, tolerability, pharmacokinetics, and immunogenicity of an intravitreal (ITV) injection of FCFD4514S in patients with Geographic Atrophy (GA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FCFD4514S | Intravitreal escalating dose |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2009-09-09
- Last updated
- 2022-12-13
Source: ClinicalTrials.gov record NCT00973011. Inclusion in this directory is not an endorsement.